The Latest Breaking News from STE

While STERIS has underperformed the broader market over the past year, analysts are highly optimistic about the stock’s prospects.

STERIS is set to report its second-quarter results next month, and analysts are projecting a double-digit rise in earnings.

STERIS has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.

The healthcare industry is poised for growth driven by the rapid adoption of new and advanced medical technologies to enhance diagnosis. Hence, investors might consider investing in healthcare stocks, such as Agilent Technologies (A), BioNTech (BNTX), and STERIS (STE), which address niche markets. Read more….

Healthcare major STERIS is expected to announce its third-quarter earnings in the upcoming month and analysts expect a modest single-digit growth in earnings.

STERIS stock has significantly underperformed the Nasdaq over the past 52 weeks, yet analysts remain strongly bullish on the stock’s prospects.

The healthcare technology market is well-poised for long-term growth, thanks to the growing demand for medical devices, cutting-edge technologies, and changing patient care systems. Thus, it could be wise to buy fundamentally solid healthcare technology stocks Zimmer Biomet Holdings (ZBH), STERIS (STE), and Tactile Systems Technology (TCMD), which are revolutionizing…

Despite STERIS’ underperformance relative to the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

STERIS will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.